Clinical Use and Perception About Synthetic Liothyronine for the Treatment of Primary Hypothyroidism Among Healthcare Professionals in India
Sameer Aggarwal, Lovely Gupta, Deepak Khandelwal, Sachin Chittawar, Shweta Sharma, Mohan T. Shenoy, Umesh K. Garg, Naima Parveen, Mona Sood · 2026
Read Clinical Use and Perception About Synthetic Liothyronine for the Treatment of Primary Hypothyroidism Among Healthcare Professionals in India by Sameer Aggarwal, Lovely Gupta, Deepak Khandelwal, Sachin Chittawar, Shweta Sharma, Mohan T. Shenoy, Umesh K. Garg, Naima Parveen, Mona Sood (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13427008.txt.
Description
Sameer Aggarwal and co-authors survey how doctors in India view and use liothyronine, a lab-made form of the thyroid hormone T3, in a 2026 study. The standard drug for an underactive thyroid has long been levothyroxine, yet a small share of patients still feel ill on it. Liothyronine reached India in 2022 but has spread slowly. The team asked 455 doctors at three teaching events about their habits.
Eight in ten doctors knew the drug, and about half had prescribed it, most often for thyroid emergencies or stubborn symptoms. High cost and poor supply were the top barriers named. Most prescribers gave it once a day, and three quarters of all doctors wanted more training on it. The authors call for clear guidelines, better teaching, and easier access.
Catalog record
| CREATOR | Sameer Aggarwal, Lovely Gupta, Deepak Khandelwal, Sachin Chittawar, Shweta Sharma, Mohan T. Shenoy, Umesh K. Garg, Naima Parveen, Mona Sood |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 29 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |